Etretinate

Jump to: navigation, search
Etretinate Wiki Str.png
Etretinate
Systematic (IUPAC) name
ethyl 9-(4-methoxy-2,3,6-trimethyl-phenyl)- 3,7-dimethyl-nona- 2,4,6,8-tetraenoate
Identifiers
CAS number 54350-48-0
ATC code D05BB01
PubChem 5282375
DrugBank DB00926
Chemical data
Formula C23H30O3 
Mol. mass 354.483 g/mol
SMILES eMolecules & PubChem
Pharmacokinetic data
Bioavailability ?
Metabolism ?
Half life 120 days
Excretion ?
Therapeutic considerations
Pregnancy cat.

?

Legal status
Routes Oral

WikiDoc Resources for Etretinate

Articles

Most recent articles on Etretinate

Most cited articles on Etretinate

Review articles on Etretinate

Articles on Etretinate in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Etretinate

Images of Etretinate

Photos of Etretinate

Podcasts & MP3s on Etretinate

Videos on Etretinate

Evidence Based Medicine

Cochrane Collaboration on Etretinate

Bandolier on Etretinate

TRIP on Etretinate

Clinical Trials

Ongoing Trials on Etretinate at Clinical Trials.gov

Trial results on Etretinate

Clinical Trials on Etretinate at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Etretinate

NICE Guidance on Etretinate

NHS PRODIGY Guidance

FDA on Etretinate

CDC on Etretinate

Books

Books on Etretinate

News

Etretinate in the news

Be alerted to news on Etretinate

News trends on Etretinate

Commentary

Blogs on Etretinate

Definitions

Definitions of Etretinate

Patient Resources / Community

Patient resources on Etretinate

Discussion groups on Etretinate

Patient Handouts on Etretinate

Directions to Hospitals Treating Etretinate

Risk calculators and risk factors for Etretinate

Healthcare Provider Resources

Symptoms of Etretinate

Causes & Risk Factors for Etretinate

Diagnostic studies for Etretinate

Treatment of Etretinate

Continuing Medical Education (CME)

CME Programs on Etretinate

International

Etretinate en Espanol

Etretinate en Francais

Business

Etretinate in the Marketplace

Patents on Etretinate

Experimental / Informatics

List of terms related to Etretinate

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Etretinate (trade name Tegison) is a medication developed by Hoffmann–La Roche that was approved by the FDA in 1986 to treat severe psoriasis. It is a second-generation retinoid. It was subsequently removed from the Canadian market in 1996 and the United States market in 1998 due to the high risk of birth defects. It remains on the market in Japan.

Properties

Etretinate has a low therapeutic index and a long elimination half-life (t1/2) of 120 days, which make dosing difficult.

Etretinate is an aromatic retinoid, and therefore highly lipophilic. It is stored and released from adipose tissue, so its effects can continue long after dosage stops. It is detectable in the plasma for up to three years following therapy.

Etretinate has been replaced by acitretin, a safer metabolite of etretinate.

Precautions

  • Etretinate is a teratogen, and may cause birth defects long after use. Therefore, birth control is advised during therapy, and for at least three years after therapy has stopped.
  • Etretinate should be avoided in children, as it may interfere with bone growth.
  • If a patient has ever taken etretinate, he or she is not eligible to donate blood, due to the risk of birth defects.[1]

Side effects

History

The drug was approved by the FDA in 1986 to treat severe psoriasis. It was subsequently removed from the Canadian market in 1996 and the United States market in 1998 due to the high risk of birth defects.[2][3]

In Japan, the drug remains on market branded Tigason.[4] People may not donate blood for two years after ceasing to use the medication.[4]

See also

References

  1. UK Blood Transfusion and Tissue Transplantation Services
  2. Qureshi, ZP; Seoane-Vazquez, E; Rodriguez-Monguio, R; Stevenson, KB; Szeinbach, SL (July 2011). "Market withdrawal of new molecular entities approved in the United States from 1980 to 2009.". Pharmacoepidemiology and drug safety. 20 (7): 772–7. PMID 21574210. doi:10.1002/pds.2155. 
  3. Fung, M.; Thornton, A.; Mybeck, K.; Wu, J. H.-h.; Hornbuckle, K.; Muniz, E. (1 January 2001). "Evaluation of the Characteristics of Safety Withdrawal of Prescription Drugs from Worldwide Pharmaceutical Markets-1960 to 1999". Therapeutic Innovation & Regulatory Science. 35 (1): 293–317. doi:10.1177/009286150103500134. 
  4. 4.0 4.1 Tigason


Template:Dermatologic-drug-stub


Linked-in.jpg